PHARMACY

Teva launches generic Protonix, Wyeth heads to court to claim damages

BY Adam Kraemer

NEW YORK Wyeth faces an uphill struggle to protect patent exclusivity for its blockbuster drug Protonix after Teva Pharmaceutical Industries Ltd. launched a generic version of the heartburn pill in the U.S. market, according to published sources.

The Israeli company had already won Food and Drug Administration for its generic, pantoprazole, approval over the summer, and had also recently seen Wyeth fail to win a preliminary injunction from a federal judge against the launch of the drug—though it is appealing the decision.

Some analysts, the Wall Street Journal reported, said the launch puts pressure on Wyeth to settle with Teva to allow marketing of a generic pill before the patent expires. However, a pre-expiry launch of this kind carries much risk along with the payoff, as a finding against Teva could cost the company as much as three times the damages to Wyeth that the launch caused. Protonix showed sales figures of $1.45 billion during the first nine months of 2007.

But Teva stated Monday that it believes it has the upper hand in the legal battle and thinks the risk for excessive damages is low. The company has agreed to refrain from shipping additional quantities of the drug during the standstill period, which expires Jan 22.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Regeneron, Sanofi-Aventis announce $312 million stock sale

BY Drew Buono

TARRYTOWN, N.Y. The biopharmaceutical company Regeneron Pharmaceuticals said yesterday that it closed a $312 million common stock sale in connection with its antibody development partnership with drug maker Sanofi-Aventis, according to published reports.

As previously agreed, Regeneron said it closed the sale of 12 million newly issued shares to Sanofi-Aventis at $26 per share. The stock purchase is part of the partnership agreement, which the companies signed Nov. 28, to discover, develop and market certain antibodies.

With the proceeds of the equity sale and an $85 million upfront payment received from Sanofi-Aventis earlier this month, Regeneron expects to end the year with $840 million to $850 million in cash and securities.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA stresses safety information for fentanyl patch

BY Drew Buono

WASHINGTON The Food and Drug Administration has issued its second safety warning about all fentanyl transdermal patches. In July 2005, the agency issued a similar warning stating that the directions on the label and on the package insert should be followed exactly in order to avoid an overdose.

The FDA, though, is still receiving reports of deaths and life-threatening side effects from doctors after hearing that the medication has been inappropriately prescribed or patients have incorrectly used them, for example, patients replacing the patch more frequently than directed in the instructions. The patch contains the opioid fentanyl, which is a powerful narcotic. The patch is approved for the treatment of persistent, moderate-to-severe pain in patients who have become opioid tolerant. The drug is usually prescribed for cancer patients.

In its Public Health Advisory and Health Care Professional Sheet published today, the FDA stressed the following safety information:

  • Fentanyl patches are only for patients who are opioid-tolerant and have chronic pain that is not well controlled with other pain medicines. The patches are not to be used to treat sudden, occasional or mild pain, or pain after surgery. 
  • Health care professionals who prescribe the fentanyl patch, and patients who use it, should be aware of the signs of fentanyl overdose: trouble breathing or slow or shallow breathing; slow heartbeat; severe sleepiness; cold, clammy skin; trouble walking or talking; or feeling faint, dizzy, or confused. If these signs occur, patients should get medical attention right away. 
  • Patients prescribed the fentanyl patch should tell their doctor, pharmacist and other health care professionals about all the medicines that they take. Some medicines may interact with fentanyl, causing dangerously high fentanyl levels in the blood and life-threatening breathing problems. 
  • Patients and their caregivers should be told how to use fentanyl patches. This important information, including instructions on how often to apply the patch, reapplying a patch that has fallen off, replacing a patch, and disposing of the patch, is provided in the patient information that comes with the fentanyl patch. 
  • Heat may increase the amount of fentanyl that reaches the blood and can cause life-threatening breathing problems and death. Patients should not use heat sources such as heating pads, electric blankets, saunas, or heated waterbeds or take hot baths or sunbathe while wearing a patch. A patient or caregiver should call the patient’s doctor right away if the patient has a temperature higher than 102 degrees while wearing a patch. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?